Preclinical studies from our group and others have demonstrated that dual inhibition of IDO1 and TDO2, especially when combined with anti-PD1 therapy, can significantly improve survival in mouse models of lung cancer (47, 48). The gene discussed is IDO1; the disease is lung cancer.